Outubro de 2021: Cabozantinibe (Cabometyx, Exelixis, Inc.) foi aprovado pela Food and Drug Administration para pacientes adultos e pediátricos de 12 anos de idade e mais velhos com tireoide diferenciada localmente avançada ou metastática.
Lenvatinib (Lenvima) New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was app..